These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 25079808)
21. Early-stage inflammation and experimental therapy in transgenic models of the Alzheimer-like amyloid pathology. Cuello AC; Ferretti MT; Leon WC; Iulita MF; Melis T; Ducatenzeiler A; Bruno MA; Canneva F Neurodegener Dis; 2010; 7(1-3):96-8. PubMed ID: 20173335 [TBL] [Abstract][Full Text] [Related]
22. The role of S100a9 in the pathogenesis of Alzheimer's disease: the therapeutic effects of S100a9 knockdown or knockout. Chang KA; Kim HJ; Suh YH Neurodegener Dis; 2012; 10(1-4):27-9. PubMed ID: 22301734 [TBL] [Abstract][Full Text] [Related]
23. Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer's disease model. Ongali B; Nicolakakis N; Tong XK; Aboulkassim T; Papadopoulos P; Rosa-Neto P; Lecrux C; Imboden H; Hamel E Neurobiol Dis; 2014 Aug; 68():126-36. PubMed ID: 24807206 [TBL] [Abstract][Full Text] [Related]
24. The behavioral, pathological and therapeutic features of the senescence-accelerated mouse prone 8 strain as an Alzheimer's disease animal model. Cheng XR; Zhou WX; Zhang YX Ageing Res Rev; 2014 Jan; 13():13-37. PubMed ID: 24269312 [TBL] [Abstract][Full Text] [Related]
25. Transthyretin stabilization by iododiflunisal promotes amyloid-β peptide clearance, decreases its deposition, and ameliorates cognitive deficits in an Alzheimer's disease mouse model. Ribeiro CA; Oliveira SM; Guido LF; Magalhães A; Valencia G; Arsequell G; Saraiva MJ; Cardoso I J Alzheimers Dis; 2014; 39(2):357-70. PubMed ID: 24169237 [TBL] [Abstract][Full Text] [Related]
26. Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD. García-Barroso C; Ricobaraza A; Pascual-Lucas M; Unceta N; Rico AJ; Goicolea MA; Sallés J; Lanciego JL; Oyarzabal J; Franco R; Cuadrado-Tejedor M; García-Osta A Neuropharmacology; 2013 Jan; 64():114-23. PubMed ID: 22776546 [TBL] [Abstract][Full Text] [Related]
27. Myeloid differentiation factor 88-deficient bone marrow cells improve Alzheimer's disease-related symptoms and pathology. Hao W; Liu Y; Liu S; Walter S; Grimm MO; Kiliaan AJ; Penke B; Hartmann T; Rübe CE; Menger MD; Fassbender K Brain; 2011 Jan; 134(Pt 1):278-92. PubMed ID: 21115468 [TBL] [Abstract][Full Text] [Related]
28. Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer's disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition. Stumm C; Hiebel C; Hanstein R; Purrio M; Nagel H; Conrad A; Lutz B; Behl C; Clement AB Neurobiol Aging; 2013 Nov; 34(11):2574-84. PubMed ID: 23838176 [TBL] [Abstract][Full Text] [Related]
29. Diet and Alzheimer's disease risk factors or prevention: the current evidence. Solfrizzi V; Panza F; Frisardi V; Seripa D; Logroscino G; Imbimbo BP; Pilotto A Expert Rev Neurother; 2011 May; 11(5):677-708. PubMed ID: 21539488 [TBL] [Abstract][Full Text] [Related]
30. Assessing the contribution of inflammation in models of Alzheimer's disease. Johnston H; Boutin H; Allan SM Biochem Soc Trans; 2011 Aug; 39(4):886-90. PubMed ID: 21787318 [TBL] [Abstract][Full Text] [Related]
31. Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease. Grammas P J Neuroinflammation; 2011 Mar; 8():26. PubMed ID: 21439035 [TBL] [Abstract][Full Text] [Related]
33. An update on clinical proteomics in Alzheimer's research. Korolainen MA; Nyman TA; Aittokallio T; Pirttilä T J Neurochem; 2010 Mar; 112(6):1386-414. PubMed ID: 20050976 [TBL] [Abstract][Full Text] [Related]
34. Dementia, diabetes, Alzheimer's disease, and insulin resistance in the brain: progress, dilemmas, new opportunities, and a hypothesis to tackle intersecting epidemics. Kuljiš RO; Salković-Petrišić M J Alzheimers Dis; 2011; 25(1):29-41. PubMed ID: 21335659 [TBL] [Abstract][Full Text] [Related]
35. Elucidating the triggers, progression, and effects of Alzheimer's disease. Medeiros R; Chabrier MA; LaFerla FM J Alzheimers Dis; 2013; 33 Suppl 1():S195-210. PubMed ID: 22635105 [TBL] [Abstract][Full Text] [Related]
36. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease. Kazim SF; Blanchard J; Dai CL; Tung YC; LaFerla FM; Iqbal IG; Iqbal K Neurobiol Dis; 2014 Nov; 71():110-30. PubMed ID: 25046994 [TBL] [Abstract][Full Text] [Related]